AstraZeneca plc (LSE: AZN) has reported another quarter of solid performance, with results for the nine months and third quarter of 2025 showing continued growth across key therapeutic areas — and a reaffirmed outlook for the full year.
Financial Highlights
For the first nine months of 2025, total revenue reached $34.7 billion, an increase of 9% at constant exchange rates (CER), driven by strength in the company’s Oncology, Cardiovascular, and Rare Disease portfolios. Core earnings per share climbed 16% at CER to $5.82, underscoring AstraZeneca’s operational efficiency and resilience amid ongoing currency headwinds.
In the third quarter alone, revenue rose to $11.6 billion, reflecting double-digit growth across Oncology, Vaccines, and Immune Therapies. The performance highlights AstraZeneca’s ability to sustain top-line expansion even as broader market conditions remain mixed.
Dividend and Guidance
The Board declared a second interim dividend of $0.935 per share, maintaining its progressive dividend policy and continuing to reward shareholders through consistent capital returns.
Management reaffirmed full-year guidance, expecting low-to-mid-teens revenue growth and high-teens EPS growth at constant exchange rates — signalling confidence in both pipeline delivery and commercial execution.
Operational Strength
AstraZeneca’s growth remains broad-based. Oncology continues to lead the portfolio, supported by expanding indications for key drugs. Meanwhile, strong performance in vaccines and immune therapies has offset slower trends in certain mature markets.
The company’s late-stage R&D pipeline remains one of the most advanced in global biopharma, with multiple regulatory submissions and trial readouts expected through 2026.
Outlook
Despite macroeconomic challenges and foreign exchange volatility, AstraZeneca’s consistent delivery and diversified portfolio place it among the most reliable growth stories in global healthcare. With a healthy balance sheet, robust cash generation, and clear pipeline momentum, the company continues to build on its position as a global pharmaceutical leader.
